Zacks: Brokerages Anticipate Aptevo Therapeutics Inc (NASDAQ:APVO) Will Announce Earnings of -$0.38 Per Share

Share on StockTwits

Equities research analysts expect Aptevo Therapeutics Inc (NASDAQ:APVO) to post ($0.38) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Aptevo Therapeutics’ earnings, with estimates ranging from ($0.48) to ($0.28). Aptevo Therapeutics reported earnings per share of ($0.58) in the same quarter last year, which would indicate a positive year-over-year growth rate of 34.5%. The firm is expected to report its next quarterly earnings results on Thursday, August 8th.

On average, analysts expect that Aptevo Therapeutics will report full year earnings of ($1.40) per share for the current year, with EPS estimates ranging from ($1.88) to ($1.10). For the next financial year, analysts anticipate that the company will post earnings of ($1.02) per share, with EPS estimates ranging from ($1.19) to ($0.84). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that follow Aptevo Therapeutics.

Aptevo Therapeutics (NASDAQ:APVO) last issued its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($0.44) EPS for the quarter, hitting the consensus estimate of ($0.44). Aptevo Therapeutics had a negative net margin of 199.24% and a negative return on equity of 122.33%. The firm had revenue of $7.02 million for the quarter, compared to analyst estimates of $6.30 million.

Several brokerages have recently commented on APVO. ValuEngine lowered shares of Zosano Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, May 1st. Roth Capital restated a “buy” rating on shares of Resverlogix in a report on Thursday, May 23rd. Zacks Investment Research downgraded shares of GENEL ENERGY PL/ADR from a “hold” rating to a “sell” rating in a research note on Thursday, July 4th. Finally, Piper Jaffray Companies upped their target price on shares of Aptevo Therapeutics from $4.00 to $4.50 and gave the stock an “overweight” rating in a research note on Monday, April 15th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $7.88.

In other Aptevo Therapeutics news, Director Zsolt Harsanyi bought 50,000 shares of the business’s stock in a transaction that occurred on Friday, June 7th. The shares were purchased at an average cost of $0.78 per share, with a total value of $39,000.00. Following the purchase, the director now directly owns 50,000 shares in the company, valued at $39,000. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last ninety days, insiders have purchased 226,961 shares of company stock worth $186,950. 11.74% of the stock is owned by insiders.

Large investors have recently made changes to their positions in the business. Marshall Wace LLP acquired a new position in shares of Aptevo Therapeutics in the 1st quarter valued at $33,000. Deutsche Bank AG boosted its holdings in shares of Aptevo Therapeutics by 251.7% in the 4th quarter. Deutsche Bank AG now owns 330,200 shares of the biotechnology company’s stock valued at $419,000 after buying an additional 236,300 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of Aptevo Therapeutics by 1.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,442,049 shares of the biotechnology company’s stock valued at $1,831,000 after buying an additional 16,482 shares in the last quarter. 36.37% of the stock is currently owned by institutional investors.

Shares of APVO stock traded down $0.01 during trading hours on Wednesday, hitting $0.87. The company had a trading volume of 207,010 shares, compared to its average volume of 540,099. The business’s fifty day moving average is $0.85. The company has a quick ratio of 2.91, a current ratio of 3.15 and a debt-to-equity ratio of 0.60. Aptevo Therapeutics has a fifty-two week low of $0.67 and a fifty-two week high of $5.80. The firm has a market capitalization of $38.79 million, a PE ratio of -0.36 and a beta of 2.39.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations.

Further Reading: How does the Beige Book influence monetary policy?

Get a free copy of the Zacks research report on Aptevo Therapeutics (APVO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aptevo Therapeutics (NASDAQ:APVO)

Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.